PCI 시술시 혈소판 당단백 GP IIb/IIIA 억제제(Abciximab)

• 영문명: Economic Value of Platelet Glycoprotein IIb/IIIa Receptor Blocker (Abciximab) for Percutaneous Coronary Intervention
• 발행기관: 대한약학회
• 저자명: 김진현(Jin Hyun Kim) 신상진(Sang Jin Shin) 김은주(Eun Ju Kim) 이영희(Young Hee Lee)
• 간행물 정보: 『약학회지』제51권 제3호 (2007년), 186~193쪽, 전체 8쪽
• 주제분류: 의약학 > 기타의약학
• 파일형태: PDF
• 발행일자: 2007.06.30

영문 초록

This study was performed to analyse the economic value of abciximab which is used in PCI to prevent high-risk patients with ischemic complications. The effectiveness of abciximab was extracted from published clinical trials by searching CCIS, and the direct medical costs relevant to using abciximab were estimated from the NHI claims database. The results in terms of cost per life-year gained (LYG) and cost per QALY gained showed that abciximab was cost-effective enough to deserve its cost. Social net benefit resulting from abciximab in PCI was estimated to be 60~70 billion Won per year.

키워드

abciximab cost-effectiveness analysis cost-benefit analysis PCI